THERAPY DOSSIER · th-b7b1c6a0d34a

Antileukinate (Ac-RRWWCR-NH2) combined with transgenic overexpression of human extracellular superoxide dismutase (EC-SOD)

Drug · Peptide (antileukinate, CXCR2 antagonist) + transgenic EC-SOD; no confident ChEMBL match, preclinical

Evidence & regulatory context

Mechanism: Peptide (antileukinate, CXCR2 antagonist) + transgenic EC-SOD; no confident ChEMBL match, preclinical
Target: Not recorded
Injury models: Other
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 22816678 ↗2012Reported benefit

Synergistic protection against hyperoxia-induced lung injury by neutrophils blockade and EC-SOD overexpression.

MouseOtherB6C3 background; transgenic mice carrying an extra copy of human EC-SOD under the SP-C promoter, and wild type littermatesn = 10 pups per group across 8 groups; 5 animals per group used…Intraperitoneal injectionAntileukinate 100 microgram/g body weight in 0.1 ml 0.9% w/…First dose given at birth as soon as litters were born, before the start of hyp…

Model: Hyperoxia-induced neonatal lung injury (95% FiO2 for 7 days from birth), compared with room air

Antileukinate significantly reduced bronchoalveolar neutrophil counts, myeloperoxidase activity, albumin leak and 8-isoprostane, and increased the reduced to oxidised glutathione ratio in both wild type and transgenic pups after hyperoxia. Antileukinate-treated transgenic pups showed significantly…

Extraction: extract · Supplied extraction confidence: 0.9. Machine-extracted fields require source verification.

Loading the evidence…